<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ferric citrate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ferric citrate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ferric citrate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="97146" href="/d/html/97146.html" rel="external">see "Ferric citrate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F26536176"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Auryxia</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F25816127"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Iron Preparations;</li>
<li>
                        Phosphate Binder</li></ul></div>
<div class="block doa drugH1Div" id="F26176318"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Each 1,000 mg ferric citrate tablet contains 210 mg of elemental (ie, ferric) iron.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="260f20d5-597c-46c0-b39a-7bd210352f76">Hyperphosphatemia in chronic kidney disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia in chronic kidney disease (dialysis dependent [labeled use] and non-dialysis dependent [off-label use]), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use in combination with dietary phosphate restriction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675420'])">Ref</a></span>). Ferric citrate is absorbed and can increase serum ferritin and transferrin saturation as well as lower erythropoietin requirements. Monitor iron status, hemoglobin, and serum phosphorus and adjust doses of ferric citrate, other iron-containing products, and erythropoiesis-stimulating agents if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28717990']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28717990'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 tablets (420 mg of elemental iron) 3 times daily with meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Dosage adjustment: Increase or decrease dose by 1 or 2 tablets (210 to 420 mg of elemental iron) per day at ≥1-week intervals as needed to obtain targeted serum phosphorus levels; an average dose of 8 to 9 tablets (1,680 to 1,890 mg of elemental iron) per day was needed to control serum phosphorus levels in a 52-week clinical trial of dialysis patients; maximum dose: 12 tablets/day (2,520 mg of elemental iron per day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6f16d9a-fb94-4888-824b-1ec12eb8d352">Iron-deficiency anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia (nondialysis-dependent chronic kidney disease): Oral:</b> 1 tablet (210 mg of elemental iron) once every other day or on Monday, Wednesday, and Friday. <b>Note:</b> Daily dosing may be reasonable in some individuals to improve adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1','lexi-content-ref-29032957','lexi-content-ref-31413088']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1','lexi-content-ref-29032957','lexi-content-ref-31413088'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991814"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50989102"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F26176319"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F26431971"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Darkening of stools (19% to 22%), diarrhea (21%), constipation (8% to 18%), nausea (10% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (7%), abdominal pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (6%)</p></div>
<div class="block coi drugH1Div" id="F25816130"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Iron overload syndromes (eg, hemochromatosis)</p></div>
<div class="block war drugH1Div" id="F26176304"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Iron toxicity: May increase serum iron, ferritin, and transferrin saturation (TSAT), which may lead to excessive elevations in iron stores.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stool discoloration: May cause discolored (dark) stools related to iron content.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Iron supplements: Patients receiving parenteral iron supplementation may require a dose reduction or discontinuation when ferric citrate is initiated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Overdose: Contains iron, a leading cause of fatal poisoning in children &lt;6 years of age. Keep out of reach of children; in case of accidental overdose, immediately contact a poison control center or a health care provider.</p></div>
<div class="block foc drugH1Div" id="F26111585"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Auryxia: Ferric iron 210 mg (ferric citrate 1 g) [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p></div>
<div class="block geq drugH1Div" id="F26111584"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26116587"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Auryxia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 GM210 MG(Fe) (per each): $8.94</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F26176339"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with meals. Do not chew or crush tablets (may discolor mouth and teeth).</p></div>
<div class="block use drugH1Div" id="F25816129"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia in chronic kidney disease (dialysis dependent), treatment:</b> For the control of serum phosphorus levels in patients with chronic kidney disease (CKD) receiving dialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency anemia: </b>Treatment of iron deficiency anemia in patients with CKD not on dialysis.</p></div>
<div class="block off-label drugH1Div" id="F57498491"><span class="drugH1">Use: Off-Label: Adult</span><p>Hyperphosphatemia in chronic kidney disease (non-dialysis dependent), treatment</p></div>
<div class="block cyt drugH1Div" id="F25882716"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F25882713"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Iron Preparations may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Preparations.  Management: Separate administration of alpha-lipoic acid from that of any iron-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral iron-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Iron Preparations. Management: No action is likely necessary for the majority of patients who only use antacids intermittently or occasionally. Consider separating doses of oral iron and antacids in patients who require chronic use of both agents and monitor for reduced iron efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Iron Preparations may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron preparations under fed conditions, but coadministration with or 2 hours after an iron preparation is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefdinir: Iron Preparations may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible. Separate doses by at least 2 hours if combined. Iron-containing infant formulas do not appear alter cefdinir pharmacokinetics, but red-appearing, non-bloody stools may develop when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Iron Preparations may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entacapone: Iron Preparations may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Preparations. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron preparations. Therapy with oral iron preparations should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa: Iron Preparations may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Iron Preparations may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron preparations and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron preparations or levothyroxine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: Iron Preparations may decrease the serum concentration of Methyldopa.  Management: Consider separating doses of methyldopa and orally administered iron preparation by 2 or more hours. Monitor for decreased efficacy of methyldopa if an oral iron preparation is initiated/dose increase, or increased efficacy if discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Iron Preparations may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron preparation as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Iron Preparations. Management: Give oral iron products at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Iron Preparations may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F26176301"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Iron overdose in pregnant patients may lead to an increased risk of fetal malformations, spontaneous abortion, and gestational diabetes. It is not known how use of ferric citrate may influence the absorption of vitamins and other nutrients required in pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron-deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021). Most studies note iron therapy improves maternal hematologic parameters; however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Use of low-dose supplemental iron is recommended for all pregnant patients beginning in the first trimester or first prenatal visit to prevent anemia at term (ACOG 2021). However, parenteral iron is recommended for the treatment of IDA in pregnant patients with chronic kidney disease due to better bioavailability and tolerability (Wiles 2019).</p></div>
<div class="block brc drugH1Div" id="F26176303"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iron is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Endogenous iron concentrations in breast milk vary by postpartum age and are lower than concentrations in the maternal plasma (Dorea 2000; Emmett 1997). Breast milk concentrations of iron are maintained in lactating patients with mild to moderate iron-deficiency anemia (IDA), but concentrations decrease if IDA is moderate to severe (El-Farrash 2012) or severe (Kumar 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Iron deficiency and IDA are associated with adverse effects in postpartum patients (eg, altered cognition, depression, fatigue) that may influence interactions with the infant. Iron supplementation in the postpartum patient should be initiated as soon as possible following delivery when gestational anemia is a concern. A product containing a ferrous salt may be preferred (WHO 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, intake of oral iron by a lactating patient does not significantly change breast milk concentrations (Dorea 2000; Emmett 1997); the effect of ferric citrate is not known. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F26176338"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adherence with prescribed diet.</p></div>
<div class="block mop drugH1Div" id="F26176341"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum iron, ferritin, and transferrin saturation (TSAT) at baseline and during therapy; serum phosphorus (periodically)</p></div>
<div class="block rer drugH1Div" id="F57852260"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Hemoglobin, whole blood:</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 12 to16 g/dL (SI: 120 to 160 g/L) (ABIM 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 13 to 18 g/dL (SI: 130 to 180 g/L) (ABIM 2023; WHO 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency (ABIM 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Ferritin, serum: <b>Note:</b> Ferritin is an acute phase reactant; levels may be elevated in the presence of inflammation or infection which is independent of iron status (WHO 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 24 to 307 ng/mL (SI: 53.9 to 689.8 picomole/L).</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 24 to 336 ng/mL (SI: 53.9 to 755 picomole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Iron, serum: 50 to 150 mcg/dL (SI: 9 to 26.9 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Total iron binding capacity, serum: 250 to 310 mcg/dL (SI: 44.8 to 55.5 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Transferrin saturation: 20% to 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Transferrin, serum: 200 to 400 mg/dL (SI: 24.6 to 49.2 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease-associated anemia:</b> To achieve and maintain target hemoglobin for patients with nondialysis-dependent chronic kidney disease, patients with a transferrin saturation (TSAT) ≤30% and a serum ferritin level ≤500 ng/mL (SI: 1,123.5 picomole/L) will often respond to iron supplementation (Gutiérrez 2021; KDIGO 2012).</p></div>
<div class="block pha drugH1Div" id="F26176308"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Hyperphosphatemia: Lowers serum phosphate by binding to dietary phosphate in the GI tract; product precipitates as insoluble ferric phosphate and is excreted in feces.</p>
<p style="text-indent:-2em;margin-left:2em;">Iron deficiency anemia: Oxidized ferric iron circulates bound to transferrin where it is incorporated into hemoglobin after it is transported through enterocytes into the blood.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50663160"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Citofer</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fexeric</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Citraphos | Fericpan | Phoscut fer</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Riona</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ABIM.1">
<a name="ABIM.1"></a>American Board of Internal Medicine. Laboratory Test Reference Ranges. <i>Lexi-Drugs</i>. UpToDate Lexidrug. Waltham, MA: UpToDate Inc. https://online.lexi.com. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34293770">
<a name="34293770"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No.233: Anemia in pregnancy. <i>Obstet Gynecol</i>. 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/34293770/pubmed" id="34293770" target="_blank">34293770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Auerbach.1">
<a name="Auerbach.1"></a>Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Keryx.1">
<a name="Keryx.1"></a>Auryxia (ferric citrate) [prescribing information]. Cambridge, MA: Keryx Biopharmaceuticals Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25468387">
<a name="25468387"></a>Block GA, Fishbane S, Rodriguez M, et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. <i>Am J Kidney Dis</i>. 2015;65(5):728-736. doi:10.1053/j.ajkd.2014.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/25468387/pubmed" id="25468387" target="_blank">25468387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29186198">
<a name="29186198"></a>Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S. Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. <i>PLoS One</i>. 2017;12(11):e0188712. doi:10.1371/journal.pone.0188712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/29186198/pubmed" id="29186198" target="_blank">29186198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10705077">
<a name="10705077"></a>Dorea JG. Iron and copper in human milk. <i>Nutrition</i>. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/10705077/pubmed" id="10705077" target="_blank">10705077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23369827">
<a name="23369827"></a>Dwyer JP, Sika M, Schulman G, et al; Collaborative Study Group. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. <i>Am J Kidney Dis</i>. 2013;61(5):759-766.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/23369827/pubmed" id="23369827" target="_blank">23369827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548016">
<a name="21548016"></a>El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. <i>Pediatr Blood Cancer</i>. 2012;58(2):233-238. doi:10.1002/pbc.23184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/21548016/pubmed" id="21548016" target="_blank">21548016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363415">
<a name="9363415"></a>Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. <i>Early Hum Dev</i>. 1997;49(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/9363415/pubmed" id="9363415" target="_blank">9363415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Keryx.2">
<a name="Keryx.2"></a>Ferric citrate [prescribing information]. New York, NY: Keryx Biopharmaceuticals; September 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710364">
<a name="30710364"></a>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: Iron deficiency anemia in pregnancy. <i>Int J Gynaecol Obstet</i>. 2019;144(3):322-324. doi:10.1002/ijgo.12740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/30710364/pubmed" id="30710364" target="_blank">30710364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28082519">
<a name="28082519"></a>Fishbane S, Block GA, Loram L, et al. Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia. <i>J Am Soc Nephrol</i>. 2017;28(6):1851-1858. doi:10.1681/ASN.2016101053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/28082519/pubmed" id="28082519" target="_blank">28082519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34514189">
<a name="34514189"></a>Gutiérrez O. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. <i>Kidney Int Rep. </i>2021;6(9):2261-2269. doi:10.1016/j.ekir.2021.05.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/34514189/pubmed" id="34514189" target="_blank">34514189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM) (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al, editors. <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. National Academies Press (US); 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2">
<a name="KDIGO.2"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for anemia in chronic kidney disease (2012). https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for anemia in chronic kidney disease. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Updated August 12, 2012. Accessed January 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675420">
<a name="30675420"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). <i>Kidney Int</i>. 2017;7(suppl 1):1-59. doi:10.1016/j.kisu.2017.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/30675420/pubmed" id="30675420" target="_blank">30675420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310187">
<a name="18310187"></a>Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. <i>Pediatrics</i>. 2008;121(3):e673-e677. doi:10.1542/peds.2007-1986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/18310187/pubmed" id="18310187" target="_blank">18310187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28717990">
<a name="28717990"></a>Locatelli F, Del Vecchio L. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?<i> J Nephrol</i>. 2017;30(6):755-765. doi:10.1007/s40620-017-0421-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/28717990/pubmed" id="28717990" target="_blank">28717990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23662073">
<a name="23662073"></a>Mutell R, Rubin JL, Bond TC, Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. <i>Int J Nephrol Renovasc Dis</i>. 2013;6:79-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/23662073/pubmed" id="23662073" target="_blank">23662073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NASEM.1">
<a name="NASEM.1"></a>National Academies of Sciences, Engineering, and Medicine. <i>Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop</i>. The National Academies Press; 2020. https://doi.org/10.17226/25841.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578718">
<a name="31578718"></a>Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. <i>Br J Haematol</i>. 2020;188(6):819-830. doi:10.1111/bjh.16221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/31578718/pubmed" id="31578718" target="_blank">31578718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33328068">
<a name="33328068"></a>Singh M. Breastfeeding and medication use in kidney disease. <i>Adv Chronic Kidney Dis</i>. 2020;27(6):516-524. doi:10.1053/j.ackd.2020.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/33328068/pubmed" id="33328068" target="_blank">33328068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29032957">
<a name="29032957"></a>Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. <i>Lancet Haematol</i>. 2017;4(11):e524-e533. doi:10.1016/S2352-3026(17)30182-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/29032957/pubmed" id="29032957" target="_blank">29032957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31413088">
<a name="31413088"></a>Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. <i>Haematologica</i>. 2020;105(5):1232-1239. doi:10.3324/haematol.2019.220830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/31413088/pubmed" id="31413088" target="_blank">31413088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24899820">
<a name="24899820"></a>Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. <i>Int J Nephrol Renovasc Dis</i>. 2014;7:191-201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/24899820/pubmed" id="24899820" target="_blank">24899820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31672135">
<a name="31672135"></a>Wiles K, Chappell L, Clark K, et al. Clinical practice guideline on pregnancy and renal disease. <i>BMC Nephrol</i>. 2019;20(1):401. doi:10.1186/s12882-019-1560-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/31672135/pubmed" id="31672135" target="_blank">31672135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583315">
<a name="27583315"></a>World Health Organization (WHO). Guideline: iron supplementation in postpartum women. Geneva: World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/27583315/pubmed" id="27583315" target="_blank">27583315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22. Published 2011. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Serum ferritin concentrations for the assessment of iron status in individuals and populations: technical brief. https://iris.who.int/bitstream/handle/10665/337666/9789240008526-eng.pdf?sequence=1. Published 2020. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24408120">
<a name="24408120"></a>Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. <i>Clin J Am Soc Nephrol</i>. 2014;9(3):543-552. doi:10.2215/CJN.05170513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-citrate-drug-information/abstract-text/24408120/pubmed" id="24408120" target="_blank">24408120</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 96959 Version 124.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
